Oncolytics Biotech Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncolytics Biotech Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: geoffb_si who wrote (64)	4/17/2002 9:46:11 AM
From: geoffb_si	Read Replies (1) of 103

Oncolytics starts Phase II Prostate Cancer Reolysin patient treatment study [Prostate] Tuesday Apr 16 2002 News Release Dr. Matt Coffey reports Oncolytics Biotech has started patient treatment in its clinical study to evaluate the efficacy of Reolysin for the treatment of T2 prostate cancer. Reolysin is the formulation of the reovirus, developed by Oncolytics as a potential therapeutic for a broad range of cancers in humans. The T2 prostate cancer trial is intended to evaluate the efficacy of intra-tumoural administration of Reolysin for the treatment of cancer that is restricted to the prostate gland. Patients will receive a single injection of Reolysin and will be monitored for approximately three weeks, at which time the prostate will be surgically removed. The primary efficacy end point will be the response rate as measured by pathological examination of the tumour. The trial is expected to enroll up to 45 patients in three or more clinical sites across Canada. Previous research has demonstrated that Reolysin is effective in killing a variety of human derived prostate cancer cell lines and it causes significant tumour regression in animal models of prostate cancer. Cancer of the prostate is one of the most common cancers in men, representing approximately one-third of all male cancers in western society. It is second only to lung cancer as the leading cause of cancer deaths in men. There are an estimated 16,600 new cases of prostate cancer in Canada and the American Cancer Society estimates that there will be 198,100 new cases in the United States in 2001. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 2002 Canjex Publishing Ltd. canada-stockwatch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next